Stock Events

Poxel 

$0.69
1
-$0.01-0.81% Friday 12:05

Statistics

Day High
0.7
Day Low
0.7
52W High
2.6
52W Low
0.55
Volume
100
Avg. Volume
1
Mkt Cap
34.07M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

16MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.53
-0.35
-0.18
0
Expected EPS
-0.43
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PXXLF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap482.65B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Poxel's focus on metabolic diseases including type 2 diabetes.
Sanofi
SNY
Mkt Cap125.78B
Sanofi is a multinational pharmaceutical company that has a strong portfolio in diabetes and cardiovascular diseases, making it a direct competitor to Poxel's diabetes treatment efforts.
Lilly(Eli) &
LLY
Mkt Cap869.21B
Eli Lilly is a major player in the diabetes care market, with a wide range of treatments that compete with Poxel's diabetes and metabolic disease focus.
Astrazeneca
AZN
Mkt Cap239.79B
AstraZeneca has a significant presence in the diabetes and metabolic disorder treatment market, competing with Poxel's product offerings.
Merck &
MRK
Mkt Cap320.27B
Merck & Co. offers diabetes treatments and solutions, directly competing with Poxel in the metabolic disease space.
Bristol-Myers Squibb
BMY
Mkt Cap80.39B
Bristol-Myers Squibb has a portfolio of diabetes treatments, positioning it as a competitor to Poxel in the metabolic disease treatment market.
Takeda Pharmaceutical
TAK
Mkt Cap41.81B
Takeda Pharmaceutical Company has a focus on metabolic disorders among its diversified healthcare solutions, competing with Poxel's diabetes treatment developments.
Molecular Templates
MTEM
Mkt Cap7.83M
Molecular Templates focuses on creating novel therapies for various diseases, including metabolic disorders, potentially competing with Poxel's research and development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap122.46B
Vertex Pharmaceuticals is involved in developing treatments for a wide range of diseases, including those related to metabolism, which could compete with Poxel's diabetes and metabolic disease treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap111.64B
Regeneron Pharmaceuticals has a broad research focus that includes metabolic and cardiovascular diseases, positioning it as a competitor to Poxel in the metabolic disease treatment market.

About

Biotechnology
Health Technology
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Show more...
CEO
Thomas Kuhn
Employees
15
Country
FR
ISIN
FR0012432516
WKN
000A14M04

Listings